Mehnaj Ahmed

Abstract 1188: Associations between Breast Cancer Index and MSK-IMPACT genomic and transcriptomic profiles in HR+ breast cancer.

Hong Zhang, Niloufar Khojandi, Natalia Siuliukina, Julia Ah-Reum An et autres

Abstract Background: The Breast Cancer Index (BCI) is a gene expression-based assay that stratifies patients based on their risk of overall (0-10 years) and late (beyond 5 years) distant recurrence. In addition , BCI can also predict the benefit of extended endocrine …

us, nz (code pays fourni par la source)

Homologous recombination deficiency and hemizygosity drive resistance in breast cancer

Anton Mikhailovich Safonov, Minna Lee, David N. Brown, Luca Boscolo Bielo et autres

The co-occurrence of germline and somatic oncogenic alterations is frequently observed in breast cancer, yet their combined influence on tumour evolution and therapy resistance remains poorly defined. Through an integrated clinicogenomic analysis of more than 5,800 patients, we show that germline (g) …

us, gb, es, it, fr (code pays fourni par la source)

Sequential use of PI3K/AKT/mTOR pathway inhibitors alpelisib and everolimus in patients with hormone receptor-positive metastatic breast cancer

Sherry Shen, Jimmitti Teysir, Anton Mikhailovich Safonov, Maria Bromberg et autres

BACKGROUND: Everolimus, an mTOR inhibitor, is FDA-approved with endocrine therapy (ET) for hormone receptor-positive (HR+)/HER2- MBC regardless of PI3K/AKT/mTOR pathway mutation status. Alpelisib, a PI3K inhibitor, is FDA-approved with fulvestrant for PIK3CA-mutant HR+/HER2- MBC. The efficacy and safety of sequential treatment with …

us (code pays fourni par la source)

Abstract P2-01-29: Prognostic value of circulating tumor DNA in metastatic breast cancer

Luc Cabel, Emanuela Ferraro, Enrico Moiso, Randy Yeh et autres

Abstract Introduction: Circulating tumor DNA (ctDNA) is widely used in the management of metastatic breast cancer (MBC) for tumor genotyping and detection of actionable alterations. Whether detectable ctDNA and its levels are associated with worse prognosis has not been well established yet …

Abstract P3-09-26: Efficacy of trastuzumab deruxtecan (T-DXd) in patients with metastatic lobular breast cancer with or without HER2 mutations: the MSKCC experience

Sherry Shen, Anton Mikhailovich Safonov, Jimmitti Teysir, Mithat Gönen et autres

Abstract Background: In patients with HER2-low metastatic breast cancer (MBC), T-DXd improves outcomes compared to chemotherapy. Metastatic invasive lobular carcinoma (mILC) is associated with lower rates of HER2 amplification compared to invasive ductal carcinoma, but higher rates of HER2 (ERBB2) mutations, which …

Abstract P1-03-16: Multimodal analyses of clinical, radiology, pathology and genomic information for enhanced prediction of response to neoadjuvant therapy in breast cancer

Sarah Eskreis‐Winkler, Francisco Sánchez-Vega, Armaan Kohli, Enrico Moiso et autres

Abstract Background: Neoadjuvant chemotherapy (NACT) is the standard of care for early-stage breast cancer patients (pts) with high-risk clinical features and pathologic complete response (pCR) is considered the best predictor of favorable long-term outcomes. We developed machine learning models to predict pCR …

Abstract GS3-09: Multimodal integration of real world clinical and genomic data for the prediction of CDK4/6 inhibitors outcomes in patients with HR+/HER2- metastatic breast cancer

Enrico Moiso, Emanuela Ferraro, Luc Cabel, Anton Mikhailovich Safonov et autres

Abstract Introduction: Addition of CDK4/6 inhibitors (CDK4/6i) to endocrine therapy (ET) have led to marked improvement of outcomes in patients (pts) with HR+/HER2− metastatic breast cancer (MBC). However, the responses vary significantly with a subset of patients experiencing early therapeutic resistance. In …

Abstract P1-11-07: Associations between Breast Cancer Index Classifications and MSK-IMPACT Genomic Profiles in HR+/HER2- Breast Cancer

Hong Zhang, Li Ma, Anton Mikhailovich Safonov, Natalia Siuliukina et autres

Abstract Background: The Breast Cancer Index (BCI) is a gene expression-based signature that stratifies patients based on the risk of overall (0-10 years) and late (post-5 years) distant recurrence (DR). BCI also predicts the likelihood of benefit from extended endocrine therapy in …

The impact of breast cancer treatment on young women’s body image and sexual health.

Shari Beth Goldfarb, Alanna Jamner, D S, Mary L. Gemignani et autres

11134 Background: In 2023 MSKCC launched the Young Women with Breast Cancer Program (YWBCP) to provide comprehensive care, education, and research studies for young women with cancer. This program explored how breast cancer treatment impacts body image, sexual health, self-esteem, and personal …

us (code pays fourni par la source)

Abstract 7109: Understanding race-specific differences in the predictive performance of computational outcome models for breast cancer

William Asinger, Sarah Eskreis‐Winkler, Armaan Kohli, Enrico Moiso et autres

Abstract Background: Neoadjuvant chemotherapy (NACT) is the standard of care for locally advanced breast tumors and pathologic complete response (pCR) is the most prominent determinant of favorable outcomes. We built computational predictors of pCR for breast cancer patients (pts) treated with NACT …

us (code pays fourni par la source)

Automated real-world data integration improves cancer outcome prediction

Justin Jee, Christopher John Fong, Karl Pichotta, Thinh Ngoc Tran et autres

The digitization of health records and growing availability of tumour DNA sequencing provide an opportunity to study the determinants of cancer outcomes with unprecedented richness. Patient data are often stored in unstructured text and siloed datasets. Here we combine natural language processing …

us (code pays fourni par la source)

Sequential use of PI3K/AKT/mTOR pathway inhibitors alpelisib and everolimus in patients with hormone receptor-positive (HR+) metastatic breast cancer.

Sherry Shen, Anton Mikhailovich Safonov, Maria Bromberg, Yuan Chen et autres

1057 Background: Alpelisib (A), a PI3K inhibitor, is FDA-approved with fulvestrant for patients with PIK3CA-mutated HR+/HER2- MBC. Everolimus (E), an mTOR inhibitor, is FDA-approved with endocrine therapy (ET) regardless of PI3K/AKT/mTOR pathway mutation status. The efficacy and safety of sequential treatment with …

us (code pays fourni par la source)